aster.cloud aster.cloud
  • /
  • Platforms
    • Public Cloud
    • On-Premise
    • Hybrid Cloud
    • Data
  • Architecture
    • Design
    • Solutions
    • Enterprise
  • Engineering
    • Automation
    • Software Engineering
    • Project Management
    • DevOps
  • Programming
    • Learning
  • Tools
  • About
  • /
  • Platforms
    • Public Cloud
    • On-Premise
    • Hybrid Cloud
    • Data
  • Architecture
    • Design
    • Solutions
    • Enterprise
  • Engineering
    • Automation
    • Software Engineering
    • Project Management
    • DevOps
  • Programming
    • Learning
  • Tools
  • About
aster.cloud aster.cloud
  • /
  • Platforms
    • Public Cloud
    • On-Premise
    • Hybrid Cloud
    • Data
  • Architecture
    • Design
    • Solutions
    • Enterprise
  • Engineering
    • Automation
    • Software Engineering
    • Project Management
    • DevOps
  • Programming
    • Learning
  • Tools
  • About
  • Technology

Boehringer Ingelheim And IBM Collaborate To Advance Generative AI And Foundation Models For Therapeutic Antibody Development

  • Dean Marc
  • November 28, 2023
  • 3 minute read

Ingelheim, Germany and Armonk N.Y., November 28, 2023 – Today, Boehringer Ingelheim and IBM (NYSE:IBM) announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. 

“We are very excited to collaborate with the research team at IBM, who share our vision of making in silico biologic drug discovery a reality,” said Andrew Nixon, Global Head of Biotherapeutics Discovery at Boehringer Ingelheim. “I am confident that by joining forces with IBM scientists we will develop an unprecedented platform for accelerated antibody discovery which will enable Boehringer to develop and deliver new treatments for patients with high unmet need.” 


Partner with aster.cloud
for your next big idea.
Let us know here.



From our partners:

CITI.IO :: Business. Institutions. Society. Global Political Economy.
CYBERPOGO.COM :: For the Arts, Sciences, and Technology.
DADAHACKS.COM :: Parenting For The Rest Of Us.
ZEDISTA.COM :: Entertainment. Sports. Culture. Escape.
TAKUMAKU.COM :: For The Hearth And Home.
ASTER.CLOUD :: From The Cloud And Beyond.
LIWAIWAI.COM :: Intelligence, Inside and Outside.
GLOBALCLOUDPLATFORMS.COM :: For The World's Computing Needs.
FIREGULAMAN.COM :: For The Fire In The Belly Of The Coder.
ASTERCASTER.COM :: Supra Astra. Beyond The Stars.
BARTDAY.COM :: Prosperity For Everyone.

Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data. “IBM has been at the forefront of creating generative AI models that extend AI’s impact beyond the domain of language,” said Alessandro Curioni, Vice President Accelerated Discovery, IBM Research. “We are thrilled to now bring IBM’s multimodal foundation model technologies to Boehringer, a leader in the development and manufacturing of antibody-based therapies, to help accelerate the pace at which Boehringer can create new therapeutics.”

Foundation models for antibody discovery

Therapeutic antibodies are central in the treatment of many diseases, including cancer, autoimmune and infectious diseases. Despite major technological advances, the discovery and development of therapeutic antibodies covering diverse epitopes remains a highly complex and time-consuming process.

Together, Boehringer and IBM researchers will aim to accelerate the antibody discovery process through in-silico methods.  The sequence, structure and molecular profile information of disease-relevant targets as well as success criteria for therapeutically relevant antibody molecules, like affinity, specificity and developability will form the basis for the in-silico generation of new human antibody sequences. These methods rely on new IBM foundation model technologies, designed to increase the speed and efficiency of antibody discovery and quality of predicted antibody candidates. 

Read More  Google Cloud Announces Plans For First Cloud Region In Malaysia To Advance The Country’s Next Phase Of Economic Development

IBM’s foundation model technologies, which have demonstrated success in generating biologics and small molecules with relevant target affinities, are used to design antibody candidates for the defined targets which are subsequently screened with AI-enhanced simulation to select and refine the best binders for the target. In a validation step, Boehringer Ingelheim will produce in mini-scales and experimentally assess the antibody candidates. Moving forward, the results from the laboratory experiments will be used to improve the in-silico methods via feedback loops.

By collaborating with leading academic and industry partners, Boehringer is building a leading digital ecosystem to enable the acceleration of drug discovery and development and create new breakthrough opportunities to transform patients’ lives.

This work also serves as the latest in IBM’s efforts to use generative AI and foundation models to accelerate discovery and creation of new biologics and small molecules. Earlier this year, the company’s generative AI model efficiently predicted physico-chemical properties of drug-like small molecules.  

The IBM biomedical foundation model technologies rely on a wide range of heterogenous, publicly available data sets, including protein-protein interactions and drug-target interactions to develop pre-trained models.  The pre-trained models are then fine-tuned on specific proprietary data of IBM’s partner to offer newly designed proteins and small molecules with the desired properties.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com

Read More  EdgeX Foundry, The Leading IoT Open Source Framework, Simplifies Deployment With The Latest Hanoi Release, New Use Cases And Ecosystem Resources

About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently, and securely.

IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity, and service.

Visit www.ibm.com for more information.


Media contacts:

IBM
Katia Moskvitch
Head of Communications, IBM Research Europe
[email protected]

Marie-Ann Maushart
Manager Communications, Brand and Social for DACH
[email protected]

Boehringer Ingelheim
Dr. Reinhard Malin
Boehringer Ingelheim Corporate Affairs
Innovation Unit Communications
[email protected]

Source: cyberpogo.com


For enquiries, product placements, sponsorships, and collaborations, connect with us at [email protected]. We'd love to hear from you!

Our humans need coffee too! Your support is highly appreciated, thank you!

Dean Marc

Part of the more nomadic tribe of humanity, Dean believes a boat anchored ashore, while safe, is a tragedy, as this denies the boat its purpose. Dean normally works as a strategist, advisor, operator, mentor, coder, and janitor for several technology companies, open-source communities, and startups. Otherwise, he's on a hunt for some good bean or leaf to enjoy a good read on some newly (re)discovered city or walking roads less taken with his little one.

Related Topics
  • AI
  • Artificial Intelligence
  • Boehringer Ingelheim
  • Generative AI
  • IBM
You May Also Like
View Post
  • Computing
  • Multi-Cloud
  • Technology

Reliance on US tech providers is making IT leaders skittish

  • May 28, 2025
View Post
  • Computing
  • Multi-Cloud
  • Technology

Examine the 4 types of edge computing, with examples

  • May 28, 2025
View Post
  • Computing
  • Multi-Cloud
  • Technology

AI and private cloud: 2 lessons from Dell Tech World 2025

  • May 28, 2025
View Post
  • Computing
  • Multi-Cloud
  • Technology

TD Synnex named as UK distributor for Cohesity

  • May 28, 2025
View Post
  • Computing
  • Multi-Cloud
  • Technology

Broadcom’s ‘harsh’ VMware contracts are costing customers up to 1,500% more

  • May 28, 2025
View Post
  • Computing
  • Multi-Cloud
  • Technology

Weigh these 6 enterprise advantages of storage as a service

  • May 28, 2025
View Post
  • Computing
  • Multi-Cloud
  • Technology

Pulsant targets partner diversity with new IaaS solution

  • May 23, 2025
View Post
  • Computing
  • Multi-Cloud
  • Technology

Growing AI workloads are causing hybrid cloud headaches

  • May 23, 2025

Stay Connected!
LATEST
  • 1
    Just make it scale: An Aurora DSQL story
    • May 29, 2025
  • 2
    Reliance on US tech providers is making IT leaders skittish
    • May 28, 2025
  • Examine the 4 types of edge computing, with examples
    • May 28, 2025
  • AI and private cloud: 2 lessons from Dell Tech World 2025
    • May 28, 2025
  • 5
    TD Synnex named as UK distributor for Cohesity
    • May 28, 2025
  • Weigh these 6 enterprise advantages of storage as a service
    • May 28, 2025
  • 7
    Broadcom’s ‘harsh’ VMware contracts are costing customers up to 1,500% more
    • May 28, 2025
  • 8
    Pulsant targets partner diversity with new IaaS solution
    • May 23, 2025
  • 9
    Growing AI workloads are causing hybrid cloud headaches
    • May 23, 2025
  • Gemma 3n 10
    Announcing Gemma 3n preview: powerful, efficient, mobile-first AI
    • May 22, 2025
about
Hello World!

We are aster.cloud. We’re created by programmers for programmers.

Our site aims to provide guides, programming tips, reviews, and interesting materials for tech people and those who want to learn in general.

We would like to hear from you.

If you have any feedback, enquiries, or sponsorship request, kindly reach out to us at:

[email protected]
Most Popular
  • Understand how Windows Server 2025 PAYG licensing works
    • May 20, 2025
  • By the numbers: How upskilling fills the IT skills gap
    • May 21, 2025
  • 3
    Cloud adoption isn’t all it’s cut out to be as enterprises report growing dissatisfaction
    • May 15, 2025
  • 4
    Hybrid cloud is complicated – Red Hat’s new AI assistant wants to solve that
    • May 20, 2025
  • 5
    Google is getting serious on cloud sovereignty
    • May 22, 2025
  • /
  • Technology
  • Tools
  • About
  • Contact Us

Input your search keywords and press Enter.